Table 2

Association between expression of sex hormone receptors and clinicopathological characteristics in gastric cancer
Variable Total patients (n= 866) Evaluable patients†
ERα (n= 848) ERβ (n= 823) PR (n= 851) AR (n= 843)
Positive No. (%) P Positive No. (%) P Positive No. (%) P Positive No. (%) P
Sex 0.496 0.166 0.522 0.313
 Female 261 29 (10.9) 221 (89.8) 58 (21.9) 81 (30.6)
 Male 605 73 (12.5) 535 (92.7) 140 (23.9) 197 (34.1)
Age, years 0.837 0.187 0.523 0.254
 ≤40 70 6 (8.8) 57 (87.7) 12 (17.6) 16 (24.2)
 ≤50 148 19 (13.2) 126 (93.3) 30 (20.7) 46 (32.2)
 ≤65 328 39 (12.0) 283 (90.1) 79 (24.5) 102 (31.9)
 >65 320 38 (12.2) 290 (93.9) 77 (24.4) 114 (36.3)
Tumor site§ 0.839 0.700 0.433 0.605
 Upper 138 19 (13.8) 123 (91.8) 25 (18.2) 52 (38.0)
 Middle 263 30 (11.8) 224 (90.3) 63 (24.3) 81 (31.9)
 Lower 416 46 (11.3) 368 (92.9) 100 (24.6) 129 (32.0)
 Diffuse 49 7 (14.3) 41 (91.1) 10 (20.4) 16 (32.7)
Tumor size, cm 0.166 0.316 0.425 0.127
 ≤2 133 22 (17.1) 117 (95.9) 28 (22.0) 52 (42.3)
 ≤3 160 21 (13.7) 134 (89.9) 29 (18.6) 50 (32.3)
 ≤5 273 30 (11.1) 243 (91.7) 67 (24.7) 84 (31.3)
 >5 300 29 (9.8) 262 (91.3) 74 (24.9) 92 (31.0)
Tumor grade <0.001 0.030 0.001 <0.001
 Well 48 15 (31.9) 53 (96.4) 19 (40.4) 22 (48.9)
 Moderate 286 47 (16.5) 274 (94.5) 77 (27.1) 127 (44.9)
 Poor 532 40 (7.8) 429 (89.7) 102 (19.6) 129 (25.0)
Lauren type 0.012 0.010 0.017 <0.001
 Intestinal 535 76 (14.4) 481 (93.0) 139 (26.3) 197 (37.6)
 Diffuse 297 21 (7.4) 250 (91.2) 55 (19.0) 68 (23.9)
 Mixed 34 5 (14.7) 25 (78.1) 4 (11.8) 13 (38.2)
T classification¶ <0.001 0.195 0.818 <0.001
 pT1 132 33 (26.0) 114 (95.0) 28 (21.7) 61 (48.8)
 pT2 142 19 (13.9) 125 (94.7) 36 (26.3) 49 (36.6)
 pT3 528 44 (8.4) 463 (90.8) 120 (23.0) 147 (28.2)
 pT4 64 6 (9.7) 54 (88.5) 14 (22.2) 21 (33.9)
N classification¶ <0.001 0.574 0.340 0.001
 pN0 309 67 (22.3) 272 (93.2) 76 (25.0) 125 (41.9)
 pN1 314 20 (6.5) 275 (90.2) 63 (20.7) 85 (28.0)
 pN2 191 13 (6.9) 165 (92.7) 43 (22.6) 52 (27.4)
 pN3 52 2 (3.9) 44 (91.7) 16 (30.8) 16 (31.4)
TNM stage¶ <0.001 0.173 0.535 <0.001
 I 187 44 (24.4) 165 (95.4) 48 (26.2) 85 (47.8)
 II 158 21 (13.5) 138 (90.8) 39 (25.3) 53 (35.1)
 III 294 23 (8.0) 253 (89.7) 61 (21.0) 74 (25.3)
 IV 227 14 (6.3) 200 (92.6) 50 (22.3) 66 (29.7)

ERα, estrogen receptor alpha; ERβ, estrogen receptor beta; PR, progesterone receptor; AR, androgen receptor. †Total patients except for inevaluable cases due to tissue loss or inadequate tissue in immunohistochemistry assay. ‡Chi-square test. §Japanese Classification of Gastric Carcinoma (3rd English edition) proposed by the Japanese Gastric Cancer Association (JGCA). ¶The 6th TNM Classification of Malignant Tumors proposed by the AJCC/UICC.

Gan et al.

Gan et al. BMC Cancer 2012 12:566   doi:10.1186/1471-2407-12-566

Open Data